Lallemand Pharma AG, based in Massagno (Switzerland) is a pharmaceutical company that specializes in the development and commercialization of respiratory products having the status of drug or medical device.
Visit Lallemand Pharma 

Products and Brands

The company oversees the business and first possesses the intellectual property rights of an immunostimulant drug known as PMBL® sublingual tablets. The original PMBL® active pharmaceutical ingredient is produced in the Lallemand GMP Pharma facility. Lallemand Pharma markets all around the world drugs containing PMBL® under different brands: Ismigen®, Immubron®, Respibron®, PIR-05® and Pulmigen®.

PMBL® is indicated in the prevention and treatment of recurrent respiratory tract infections. Lallemand Pharma also developed a new line of nasal sprays that contain a postbiotic ingredient derived from a Lallemand proprietary marine bacteria called Symbiofilm®. Symbiofilm® demonstrates to prevent and reduce the development of pathogenic biofilms by mechanical action and also reduces the attachment of respiratory viruses on the nasal mucosa. Symbiofilm® also creates its own protective biofilm.

The line of nasal sprays containing Symbiofilm® can be proposed either with a bag on valve technology or with manual spray pump, enjoys a CE marking allowing commercialization all over Europe since April 2021 as well as distribution worldwide.